



# Pfizer Pipeline

---

August 11, 2011

---

# Disclaimer



- As some programs are still confidential, some candidates may not be identified in this list. In these materials, Pfizer discloses Mechanism of Action (MOA) information for candidates from Phase 3 through regulatory approval. With a view to expanding the transparency of our pipeline, Pfizer is including new indications or enhancements, which target unmet medical need or represent significant commercial opportunities. The information contained on these pages is correct as of August 11, 2011.
- Visit [Pfizer.com/pipeline](http://Pfizer.com/pipeline), Pfizer's online database where you can learn more about our portfolio of new medicines and find out more about our Research and Development efforts around the world.



# Table of Contents

<b>Pfizer Pipeline Snapshot</b>	<b>4</b>
<b>Cardiovascular &amp; Metabolic Diseases</b>	<b>5</b>
<b>Inflammation &amp; Immunology</b>	<b>6</b>
<b>Neuroscience &amp; Pain</b>	<b>7</b>
<b>Oncology</b>	<b>9</b>
<b>Vaccines</b>	<b>10</b>
<b>Other Areas of Focus</b>	<b>11</b>
<b>Projects Discontinued Since Last Update</b>	<b>12</b>

# Pfizer Pipeline Snapshot



# Pfizer Pipeline – August 11, 2011

Therapeutic Area	Compound Name	Mechanism of Action (Phase 3 through regulatory approval)	Indication	Phase
Cardiovascular and Metabolic Diseases	Viviant	Selective Estrogen Receptor Modulator	Osteoporosis Treatment and Prevention	Registration
	Pristiq	Serotonin Norepinephrine Reuptake Inhibitor	Vasomotor Symptoms of Menopause	Registration
	Eliquis (apixaban)	Factor Xa Inhibitor	Venous Thromboembolism Prevention (U.S.) <i>(Approved in the E.U.)</i>	Phase 3
	Eliquis (apixaban)	Factor Xa Inhibitor	Atrial Fibrillation	Phase 3
	Eliquis (apixaban)	Factor Xa Inhibitor	Venous Thromboembolism Treatment	Phase 3
	PF-04971729		Diabetes Mellitus-Type 2	Phase 2
	▶ PF-04991532		Diabetes Mellitus-Type 2	Phase 2
	▶ RN316 (PF-04950615)		Hypercholesterolemia (Biologic)	Phase 2
	CVX 096 (PF-04856883)		Diabetes Mellitus-Type 2 (Biologic)	Phase 1
	OAP-189 (PF-05212389)		Diabetes Mellitus-Type 2, Obesity (Biologic)	Phase 1
	PF-03882845		Diabetic Nephropathy	Phase 1
	PF-04620110		Diabetes Mellitus-Type 2	Phase 1
	PF-04937319		Diabetes Mellitus-Type 2	Phase 1
	PF-05231023		Diabetes Mellitus-Type 2 (Biologic)	Phase 1
	PF-05175157		Diabetes Mellitus-Type 2	Phase 1
	PF-05190457		Diabetes Mellitus-Type 2	Phase 1
PF-04840082		Osteoporosis Treatment and Prevention (Biologic)	Phase 1	



New Molecular Entity

New Indication or Enhancement

▶ Indicates that the project is either new or has progressed in phase since the previous portfolio update of Pfizer.com

# Pfizer Pipeline – August 11, 2011 (cont'd)

Therapeutic Area	Compound Name	Mechanism of Action (Phase 3 through regulatory approval)	Indication	Phase
Inflammation and Immunology	tofacitinib (CP-690550)	JAK Inhibitor	Rheumatoid Arthritis	Phase 3
	tofacitinib (CP-690550)	JAK Inhibitor	Psoriasis (Oral)	Phase 3
	PF-04171327		Rheumatoid Arthritis	Phase 2
	SBI-087 (PF-05230895)		Rheumatoid Arthritis, *Lupus (Biologic)	Phase 2
	ozoralizumab (ATN-103)		Rheumatoid Arthritis (Biologic)	Phase 2
	PF-05285401		Ulcerative Colitis (Biologic)	Phase 2
	anrukinzumab (IMA-638)		Ulcerative Colitis (Biologic)	Phase 2
	PF-00547659		Crohn's Disease (Biologic)	Phase 2
	PF-04236921		Crohn's Disease, *Rheumatoid Arthritis, *Lupus (Biologic)	Phase 2
	PF-04136309		Liver Fibrosis	Phase 2
	tofacitinib (CP-690550)		Psoriatic Arthritis, Ankylosing Spondylitis, Psoriasis (Topical), Crohn's Disease, Ulcerative Colitis	Phase 2
	SD-6010		Osteoarthritis	Phase 2
	PF-04308515		Anti-Inflammatory	Phase 1
	ATR-107 (PF-05230900)		Crohn's Disease (Biologic)	Phase 1
	PF-05230905 (ATN-192)		Rheumatoid Arthritis (Biologic)	Phase 1
PF-04634817		Liver Fibrosis	Phase 1	

\* Note: Additional indications in Phase 1

New Molecular Entity

New Indication or  
Enhancement



# Pfizer Pipeline – August 11, 2011 (cont'd)

Therapeutic Area	Compound Name	Mechanism of Action (Phase 3 through regulatory approval)	Indication	Phase
Neuroscience & Pain	Vyndaqel (tafamidis meglumine)	Transthyretin (TTR) Dissociation Inhibitor	Transthyretin familial amyloid polyneuropathy (E.U.) <i>(In Phase 3 in the U.S.)</i>	Registration
	Celebrex	COX-2	Chronic Pain	Registration
	Immediate release oxycodone with Aversion® technology (with niacin) (formerly acurox) (King)	Mu-type opioid receptor (MOR-1) Agonist	Moderate to Severe Pain	Registration
	Remoxy (King)	Mu-type opioid receptor (MOR-1) Agonist	Moderate to Severe Pain	Registration
	ALO-02 Oxycodone-naltrexone core (King)	Mu-type opioid receptor (MOR-1) Agonist	Moderate to Severe Pain	Phase 3
	bapineuzumab	Beta Amyloid Inhibitor	Alzheimer's Disease (Biologic)	Phase 3
	latrepirdine (Dimebon)	MpTp Modulator	Alzheimer's Disease	Phase 3
	Lyrica	Alpha-2 Delta Ligand	Epilepsy Monotherapy	Phase 3
	Lyrica	Alpha-2 Delta Ligand	Central Neuropathic Pain due to Spinal Cord Injury	Phase 3
	Lyrica	Alpha-2 Delta Ligand	Peripheral Neuropathic Pain (U.S.)	Phase 3
	tanezumab	Nerve Growth Factor Inhibitor	OA Signs and Symptoms (Biologic) (On Clinical Hold)	Phase 3
	Lyrica	Alpha-2 Delta Ligand	QD (once a day dosing)	Phase 3

New Molecular Entity

New Indication or Enhancement



# Pfizer Pipeline – August 11, 2011 (cont'd)

Therapeutic Area	Compound Name	Mechanism of Action (Phase 3 through regulatory approval)	Indication	Phase
Neuroscience & Pain  (cont'd)	PF-02545920		Schizophrenia	Phase 2
	PF-04494700		Alzheimer's Disease	Phase 2
	CP-601,927		Depression	Phase 2
	Eladur (King)		Chronic Pain	Phase 2
	PF-03049423		Stroke Recovery	Phase 2
	tanezumab		Cancer Pain (Biologic)	Phase 2
	PF-05236812 (AAB-003)		Alzheimer's Disease (Biologic)	Phase 1
	PF-04958242		Schizophrenia	Phase 1
	Vabicaserin (PF-05208769)		Schizophrenia	Phase 1
	PF-05212377 (SAM-760)		Alzheimer's Disease	Phase 1
	PF-04427429		Migraine (Biologic)	Phase 1
	PF-05089771		Chronic Pain	Phase 1
	PF-04531083		Severe Chronic Pain	Phase 1
PF-04995274		Alzheimer's Disease	Phase 1	

New Molecular Entity

New Indication or  
Enhancement





# Pfizer Pipeline – August 11, 2011 (cont'd)

Therapeutic Area	Compound Name	Mechanism of Action (Phase 3 through regulatory approval)	Indication	Phase
Oncology	▶ PF-02341066 (crizotinib)	c-MET-ALK Inhibitor	ALK-Positive Advanced Non-Small Cell Lung Cancer (accelerated approval) (U.S.)	Registration
	▶ axitinib	VEGF Tyrosine Kinase Inhibitor	Advanced Renal Cell Carcinoma (U.S.) Advanced Renal Cell Carcinoma after failure of prior systemic treatment (E.U.)	Registration
	PF-00299804 (dacomitinib)	pan-HER Inhibitor	Lung Cancer	Phase 3
	bosutinib	Abl and src-family kinase inhibitor	Chronic Myelogenous Leukemia	Phase 3
	PF-02341066 (crizotinib)	c-MET-ALK Inhibitor	ALK-Positive 1 <sup>st</sup> and 2 <sup>nd</sup> Line Non-Small Cell Lung Cancer, *Cancer	Phase 3
	axitinib	VEGF Tyrosine Kinase Inhibitor	Advanced Renal Cell Carcinoma in treatment-naïve patients	Phase 3
	neratinib	pan-HER Inhibitor	Breast Cancer	Phase 3
	Sutent	Multiple Tyrosine Kinase Inhibitor	Renal Cell Carcinoma Adjuvant	Phase 3
	Torisel	FKBP-Rapamycin Associated Protein	Renal Cell Carcinoma	Phase 3
	inotuzumab ozogamicin		Aggressive Non-Hodgkin's Lymphoma (Biologic)	Phase 3
	inotuzumab ozogamicin		Indolent Non-Hodgkin's Lymphoma (Biologic)	Phase 2
	axitinib		Lung Cancer, Thyroid Cancer	Phase 2
	PF-00299804 (dacomitinib)		Cancer	Phase 2
	PD-0332991		Cancer	Phase 2
	CVX 060 (PF-04856884)		Cancer (Biologic)	Phase 1
	CVX 241 (PF-05057459)		Cancer (Biologic)	Phase 1
	PF-03084014		Cancer	Phase 1
	PF-03446962		Cancer (Biologic)	Phase 1



New Molecular Entity

New Indication or Enhancement

▶ Indicates that the project is either new or has progressed in phase since the previous portfolio update of Pfizer.com

\* Note: Additional indications in Phase 1

# Pfizer Pipeline – August 11, 2011 (cont'd)

Therapeutic Area	Compound Name	Mechanism of Action (Phase 3 through regulatory approval)	Indication	Phase
<b>Oncology (cont'd)</b>	PF-05212384		Cancer	Phase 1
	▶ PD-0325901		Cancer (in combination with PF-04691502)	Phase 1
	▶ PF-05082566		Cancer (Biologic)	Phase 1
	PF-04554878		Cancer	Phase 1
	PF-04605412		Cancer (Biologic)	Phase 1
	PF-04691502		Cancer	Phase 1
	PF-04449913		Cancer	Phase 1
<b>Vaccines</b>	Prevenar/Prevnar 13 Adult	Prophylactic Vaccine	Pneumococcal Disease	Registration
	ACC-001 (PF-05236806)		Alzheimer's Disease	Phase 2
	MnB rLP2086 (PF-05212366)		Adolescent Meningitis, *Infant Meningitis	Phase 2
	▶ 4-Antigen Staphylococcus Aureus Vaccine (SA4Ag) (PF-06290510)		Staph Aureus	Phase 1
	3-Antigen Staphylococcus Aureus Vaccine (SA3Ag) (PF-05230894)		Staph Aureus	Phase 1

New Molecular Entity

New Indication or  
Enhancement

▶ Indicates that the project is either new or has progressed in phase since the previous portfolio update of Pfizer.com

\* Note: Additional indications in Phase 1



# Pfizer Pipeline – August 11, 2011 (cont'd)

Therapeutic Area	Compound Name	Mechanism of Action (Phase 3 through regulatory approval)	Indication	Phase
Other Areas of Focus	Taliglucerase alfa	Enzyme Replacement Therapy	Gaucher Disease (Biologic)	Registration
	Xiapex (E.U.)	Clostridial Collagenase for Injection	Peyronie's Disease (Biologic) (E.U.)	Phase 3
	Eraxis/Vfend	Beta-D Glucan Synthase Inhibitor, Cyp P450 Mediated Alpha-lanosterol Demethylation	Aspergillosis	Phase 3
	Zithromax/chloroquine	5-OS Ribosome Inhibitor	Malaria	Phase 3
	bazedoxifene-conjugated estrogens (Aprela)	Tissue Selective Estrogen Complex	Menopausal Vasomotor Symptoms	Phase 3
	bosutinib		Autosomal Dominant Polycystic Kidney Disease	Phase 2
	PF-00868554 (filibuvir)		Hepatitis C Virus	Phase 2
	tofacitinib (CP-690550)		Transplant Rejection, Dry Eye	Phase 2
	PH-797804		Chronic Obstructive Pulmonary Disease	Phase 2
	▶ PNU-100480		Tuberculosis	Phase 2
	PF-00489791		Chronic Renal Failure	Phase 2
	RN6G (PF-04382923)		Age-Related Macular Degeneration (Biologic)	Phase 1
	PF-03715455		Chronic Obstructive Pulmonary Disease	Phase 1
	PF-04764793 (PF-00241939)		Asthma	Phase 1

New Molecular Entity

New Indication or Enhancement

▶ Indicates that the project is either new or has progressed in phase since the previous portfolio update of Pfizer.com



# Projects Discontinued from Development since May 12, 2011

Compound Name	Mechanism of Action (Phase 3 through regulatory approval)	Indication	Phase
Macugen	Extracellular VEGF Antagonist	Diabetic Macular Edema (Biologic) (E.U.)	Registration
Moxidectin	glutamate-gated chloride channel binding	Onchocerciasis (River Blindness)	Phase 3
fezakinumab (ILV-094)		Rheumatoid Arthritis, *Psoriasis (Biologic)	Phase 2
PF-00610355		Chronic Obstructive Pulmonary Disease	Phase 2
PF-01367338		Cancer	Phase 2
PF-04217329 (taprenepag isopropyl)		Glaucoma	Phase 2
PF-04523655		Diabetic Macular Edema, Age-Related Macular Degeneration (Biologic)	Phase 2
PF-04360365 (ponezumab)		Alzheimer's Disease (Biologic)	Phase 2
Terguride		Pulmonary Arterial Hypertension	Phase 2
PF-00489791		Raynaud's Syndrome	Phase 2
ILV-095 (PF-05212368)		Psoriasis (Biologic)	Phase 1
BMP-655 (PF-05208762)		Tendon Repair (Biologic)	Phase 1
PF-05230901		Cachexia (Biologic)	Phase 1
PF-03758309		Cancer	Phase 1

New Molecular Entity

New Indication or Enhancement

\* Note: Additional indications in Phase 1

